Daily Cancer News
CancerConsultants provides summaries of new treatment strategies as they are discovered and reported by cancer physicians around the world. Our medical staff attends medical meetings worldwide and reviews medical literature daily to ensure appropriate news is provided to cancer patients and their families in a timely manner.
Cancer Consultants syndicated news service has been providing over 160 cancer advocacy, clinic, and hospital websites with an average of 550 news items per year since 1996. Subscribers include the Susan Komen Foundation, University of Florida Shands Cancer Center, The Prostate Cancer Research Foundation and leading clinics throughout the US.
News of the results of recent clinical trials evaluating cancer therapies and supportive care strategies serve to educate patients regarding new treatment strategies for cancer and facilitate discussions with their doctor. Importantly News also provides healthcare provider websites with fresh information daily which is key to ensuring patients use their website and enhancing search engine optimization.
Latest Cancer News
Komen Will Continue to Provide Funding To Planned Parenthood (February 3, 2012)
News broke earlier this week that Susan G. Komen for the Cure was halting grant funding to Planned Parenthood for breast health education and screening, but Komen announced today that it has reversed its... Continue Reading
In a Phase III clinical trial, the investigational drug radium-223 chloride improved survival and delayed bone complications among men with hormone-refractory prostate cancer and bone metastases. These... Continue Reading
After almost 20 years, new treatments emerge. By Mia James Melanoma is considered the deadliest form of skin cancer. Survival rates for melanoma fall dramatically once the disease has spread to other... Continue Reading
Among men with metastatic, hormone-refractory prostate cancer, treatment with the investigational drug MDV3100 delayed cancer progression and improved overall survival. These results will be presented... Continue Reading
The US Food and Drug Administration (FDA) has approved the targeted therapy Erivedge™ (vismodegib) for the treatment basal cell carcinoma of the skin that has spread to other parts of the body or that... Continue Reading
The US Food and Drug Administration has approved Inlyta® (axitinib) for the treatment of advanced renal cell (kidney) cancer that has not responded to another drug used for this condition. Inlyta is a... Continue Reading
Among women with HER2-negative breast cancer that has not spread to distant sites in the body, the addition of Avastin to neoadjuvant (before-surgery) chemotherapy may increase the likelihood of a complete... Continue Reading
Among women with ovarian cancer, those who have a BRCA1 or BRCA2 gene mutation appear to have better overall survival than those who do not have a BRCA gene mutation. These results were published in the Journal... Continue Reading
Among men who choose active surveillance for early-stage prostate cancer, Avodart® (dutasteride) may delay cancer progression and the need for cancer treatment. These results were published in The Lancet. The... Continue Reading
For patients with uncommon brain tumors known as oligodendrogliomas, the presence of a specific chromosomal abnormality is linked with a better prognosis and responsiveness to chemotherapy. These results... Continue Reading
A test that detects a particular protein in the blood (PAM4) correctly identified roughly two-thirds of patients with early-stage pancreatic cancer. These results were presented at the 2012 Gastrointestinal... Continue Reading
Zelboraf® (vemurafenib) improves outcomes among patients with advanced melanoma that harbors a BRAF gene mutation, but also accelerates the development of squamous cell carcinoma in some patients. A study... Continue Reading
